

FAX: 470.922.3656 | PHONE: 470.377.6400

PATIENT INFORMATION:	Fax completed form, ins	surance information, and clinical documentation to	470.922.3656
Patient Name:		_ DOB: Phone:	
Patient Status: New to Therapy	Continuing Therapy	Next Treatment Date:	
MEDICAL INFORMATION			
Diagnosis: Paroxysmal nocturnal hemoglobinuria (PNH) (ICD-10 Code: D59.5) Atypical hemolytic uremic syndrome (aHUS) (ICD-10 Code: D59.3) Myasthenia Gravis (gMG) w/out acute exacerbation (ICD-10 Code: G70.00) gMG Classification: II II III Neuromyelitis Optica Spectrum disorders (NMOSD) (ICD-10 Code: G36.0) Other: (ICD-10 Code:)			
Patient Weight: Ibs. (required) Allergies:			
THERAPY ORDER			
Soliris Adult Dosing:			
PNH Diagnosis- □ Initial Start: 600mg IV weekly for the first 4 weeks, followed by 900mg IV for the fifth dose 1 week later, then 900mg IV every 2 weeks thereafter x 1 year □ Maintenance Dose: 900mg IV every 2 weeks x 1 year aHUS, gMG, and NMOSD Diagnosis- □ Initial Start: 900mg IV weekly for the first 4 weeks, followed by 1200mg IV for the fifth dose 1 week later, then 1200mg IV every 2 weeks thereafter x 1 year □ Maintenance Dose: 1200mg IV every 2 weeks x 1 year 			
Lab orders:		Frequency:	
Required labs to be drawn by: \Box Bioc			
Other orders:			
 Anaphylactic Reaction Orders: Epinephrine (based on patient weight) >30kg (>66lbs): EpiPen 0.3mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1 15-30kg (33-66lbs): EpiPen Jr. 0.15mg or compounded syringe IM or subQ; may repeat in 5-10 minutes x1 Diphenhydramine: Administer 25-50mg orally OR IV (adult) Refer to physician order or institutional protocol for pediatric dosing Flush orders: NS 1-20mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN 			
PROVIDER INFORMATION			
agent in dealing with medical and prescription insurance compan Provider Name: Provider NPI: Phone: □Opt out of Biocare Infusion selecting	ies, and to select the preferred site of o	to serve as your prior authorization and specialty pharmacy design care for the patient (; Contact Person; , please list site of care);	
PREFERRED LOCATION City:		View our locations here:	

BIOCAREINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR SOLIRIS (ECULIZUMAB) THERAPY

PATIENT INFORMATION:	
Patient Name:	DOB:
REQUIRED DOCUMENTATION FOR REFERRAL P	ROCESSING & INSURANCE APPROVAL
 Include signed and completed order (MD/presson Prescriber enrolled in REMS Include patient demographic information and in Include patient's medication list Supporting clinical notes (H&P) to support prime failed therapies, intolerance, outcomes, or communication MG-ADL score (gMG diagnosis): 	nsurance information hary diagnosis including past tired and traindications to conventional therapy
Previous or current therapies:	
aHUS - The following have been ruled ou	uremic syndrome (STEC-HUS) \Box Yes \Box No
 AchR antibody (gMG diagnosis) AQP4 antibody (NMOSD diagnosis) CBC and CMP (aHUS diagnosis) Diagnostic testing to support diagnosis Flow Cytometry Test (PNH diagnosis) Abnormal Neuromuscular Transmission for CBC and CMP (aHUS and PNH diagnosis) CBC and CMP (aHUS and PNH diagnosis) Is the patient enrolled in OneSource? Patient may enroll in One Source by calling Other medical necessity: 	is)] Yes 🔲 No

REQUIRED PRE-SCREENING

Has the patient had both meningococcal vaccines (MenACWY and Men B)? Yes No

Attach proof of meningococcal vaccines - both vaccines are required prior to therapy

Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.